



an Akzo Nobel company

June 4, 2007

Richard Wood
Chair of KAW's Steering Committee
PO Box 14590
Chicago
IL 60614

RE: Your letter May 9, 2007

Dear Mr Wood:

Thank you for your letter on behalf of the Keep Antibiotics Working coalition, outlining your concerns over Intervet's application for the approval of cefquinome for the treatment of bovine respiratory disease.

Intervet disagrees with KAW's conclusion and believes the current scientific data adequately supports approval of the application under the standards established by the FDA. You may be assured that Intervet continues to evaluate all the available scientific data as well as the matters addressed in KAW's letter and the recent VMAC meeting. Intervet fully supports the science-based regulatory process outlined in Guideline #152 and remains confident that the FDA has the necessary expertise, procedures and mitigation measures in place to evaluate the scientific data and make the appropriate legal and public health determinations regarding the cefquinome application.

Intervet promotes the responsible and prudent use of antibiotics and feels antibiotics like cefquinome play a critical role in the treatment of important bacterial diseases in food producing animals. In Europe, various injectable and intramammary formulations of cefquinome are marketed solely under prescription for a number of indications in cattle, pigs and horses. Current approvals for use of cefquinome in Europe and those being sought in the United States are limited to individual animal treatment. Intervet has not sought and does not anticipate any approvals for use via water or feed for the purposes of whole herd treatment or growth promotion with this molecule.

Intervet has directly conducted and supported resistance monitoring programs across Europe since the introduction of cefquinome in 1994. Such programs¹ have included both animal pathogens and food borne bacteria of human health concern. The European experience to date provides substantial evidence that prudent use of cefquinome, as indicated by its label approvals, poses no risk to public health.

While Intervet understands that KAW may disagree with its conclusions, we feel it important to make clear the reasons why we believe continuing to seek approval of this important new drug to treat bovine respiratory disease is both responsible and appropriate.

Sincerely,

Chris Ragland
President Intervet Inc.

¹ European Antimicrobial Susceptibility Surveillance in Animals (EASSA) program, European (VetPath) and Dutch (MARAN) surveillance program, German surveillance program (Germ-Vet)

